About Professor Luke Howard

Respiratory Consultant

Lung Health

Sub-specialties: Cardiopulmonary Exercise Test (CPET), Pulmonary Embolism, Pulmonary Hypertension, Right Heart Catheterisation, Breathlessness, Exercise Intolerance, Respiratory Medicine.

Professor Howard is also a Professor of Practice (Cardiopulmonary Medicine) at the National Heart & Lung Institute, Imperial College London. He is also an honorary Consultant Pulmonologist at St Bartholomew’s Hospital.

Overview

Bookings: bookings.lunghealth@onewelbeck.com

Tel: 020 3653 2006

Professor Howard is also a Professor of Practice (Cardiopulmonary Medicine) at the National Heart & Lung Institute, Imperial College London. He is also an honorary Consultant Pulmonologist at St Bartholomew’s Hospital.

Areas of Expertise

Professor Howard treats various conditions including the following:

  • Unexplained breathlessness and exercise intolerance
  • Pulmonary embolism
  • Pulmonary hypertension

Some of the treatments and procedures he offers are:

About Professor Luke Howard

Professor Howard  has expertise in diseases of pulmonary circulation, including pulmonary hypertension (high blood pressure in the lung) and pulmonary embolism (blood clots in the lung); sport and exercise physiology; unexplained breathlessness.

Alongside his work at OneWelbeck, Professor Howard is a Consultant Pulmonologist at Imperial College Healthcare NHS Trust and Director of Pulmonary Hypertension Service and a Clinical lead for exercise physiology. Professor Howard is also a Professor of Practice (Cardiopulmonary Medicine) at the National Heart & Lung Institute, Imperial College London. He is also an honorary Consultant Pulmonologist at St Bartholomew’s Hospital.

Personal Biography

Professor Luke Howard completed his undergraduate training in Physiological Sciences at the University of Oxford, which he followed directly with his research doctorate, also at Oxford, in Altitude Physiology. He moved to the University of Cambridge to complete his clinical studies. He acquired his general medical training in London at the Royal Brompton Hospital and Guys and St Thomas’ Hospital and then undertook specialist training in Cambridge and Papworth before moving back to London to take up his current consultant position.

Professor Howard was appointed Consultant Pulmonologist to the National Pulmonary Hypertension Service at Hammersmith Hospital, Imperial College Healthcare NHS Trust, London in 2006. He also holds an honorary Clinical Senior Lecturer post at the National Heart and Lung Institute, Imperial College London. He runs the Exercise Physiology Service, based at Hammersmith Hospital.

He has an active research programme in Pulmonary Hypertension and Exercise Physiology, as well as sitting on national and international committees and guideline groups for pulmonary hypertension, pulmonary embolism, oxygen therapy and air travel. He is regarded as an international expert, lecturing around the world in his areas of interest.

Additional Information

Awards

  • National Clinical Excellence Award – Bronze April 2013
  • National Clinical Excellence Award – Silver April 2017
  • William Harvey Scholarship – University of Cambridge 1994

Memberships

  • Fellow of Royal College of Physicians
  • Member of European Respiratory Society and British Thoracic Society

Research Highlights

Main research interests

  • Early phase clinical studies in pulmonary hypertension examining new targets with novel clinical end-points.
  • Use of wearables in telemedicine and clinical trials

Notable Publications

  • Cannon, J. E., L. Su, D. G. Kiely, K. Page, M. Toshner, E. Swietlik, C. Treacy, A. Ponnaberanam, R. Condliffe, K. Sheares, D. Taboada, J. Dunning, S. Tsui, C. Ng, D. Gopalan, N. Screaton, C. Elliot, S. Gibbs, L. Howard, P. Corris, J. Lordan, M. Johnson, A. Peacock, R. MacKenzie-Ross, B. Schreiber, G. Coghlan, K. Dimopoulos, S. J. Wort, S. Gaine, S. Moledina, D. P. Jenkins and J. Pepke-Zaba (2016). “Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.” Circulation 133(18): 1761-1771.  https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.115.019470
  • Charalampopoulos, A., J. S. Gibbs, R. J. Davies, W. Gin-Sing, K. Murphy, K. K. Sheares, J. Pepke-Zaba, D. P. Jenkins and L. S. Howard (2016). “Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.” J Appl Physiol (1985) 121(3): 623-628.  https://journals.physiology.org/doi/pdf/10.1152/japplphysiol.00087.2016
  • Ghofrani, H. A., G. Simonneau, A. M. D’Armini, P. Fedullo, L. S. Howard, X. Jais, D. P. Jenkins, Z. C. Jing, M. M. Madani, N. Martin, E. Mayer, K. Papadakis, D. Richard, N. H. Kim and M. s. investigators (2017). “Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.” Lancet Respir Med 5(10): 785-794.  https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30305-3/fulltext
  • Howard, L., S. Barden, R. Condliffe, V. Connolly, C. W. H. Davies, J. Donaldson, B. Everett, C. Free, D. Horner, L. Hunter, J. Kaler, C. Nelson-Piercy, O. D. E, R. Patel, W. Preston, K. Sheares and T. Campbell (2018). “British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).” Thorax 73(Suppl 2): ii1-ii29.  https://thorax.bmj.com/content/73/Suppl_2/ii1
  • Kovacs, G., P. Herve, J. A. Barbera, A. Chaouat, D. Chemla, R. Condliffe, G. Garcia, E. Grunig, L. Howard, M. Humbert, E. Lau, P. Laveneziana, G. D. Lewis, R. Naeije, A. Peacock, S. Rosenkranz, R. Saggar, S. Ulrich, D. Vizza, A. Vonk Noordegraaf and H. Olschewski (2017). “An official European Respiratory Society statement: pulmonary haemodynamics during exercise.” Eur Respir J 50(5).  https://erj.ersjournals.com/content/50/5/1700578
  • McGoon, M. D., P. Ferrari, I. Armstrong, M. Denis, L. S. Howard, G. Lowe, S. Mehta, N. Murakami and B. A. Wong (2019). “The importance of patient perspectives in pulmonary hypertension.” Eur Respir J 53(1).   https://erj.ersjournals.com/content/53/1/1801919.abstract
  • Rosenkranz, S., L. S. Howard, M. Gomberg-Maitland and M. M. Hoeper (2020). “Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure.” Circulation 141(8): 678-693.   https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.022362
  • Rothman, A. M. K., J. L. Vachiery, L. S. Howard, G. W. Mikhail, I. M. Lang, M. Jonas, D. G. Kiely, D. Shav, O. Shabtay, A. Avriel, G. D. Lewis, E. B. Rosenzweig, A. J. Kirtane, N. H. Kim, E. Mahmud, V. V. McLaughlain, S. Chetcuti, M. B. Leon, O. Ben-Yehuda and L. J. Rubin (2020). “Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study.” JACC Cardiovasc Interv 13(8): 989-999.  https://interventions.onlinejacc.org/content/13/8/989
  • Su, J., C. Manisty, K. H. Parker, U. Simonsen, J. E. Nielsen-Kudsk, S. Mellemkjaer, S. Connolly, P. B. Lim, Z. I. Whinnett, I. S. Malik, G. Watson, J. E. Davies, S. Gibbs, A. D. Hughes and L. Howard (2017). “Wave Intensity Analysis Provides Novel Insights Into Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.” J Am Heart Assoc 6(11).  https://pubmed.ncbi.nlm.nih.gov/29089339/
  • Zhai, Z., K. Murphy, H. Tighe, C. Wang, M. R. Wilkins, J. S. Gibbs and L. S. Howard (2011). “Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.” Chest 140(5): 1284-1291.  https://doi.org/10.1378/chest.10-335